Overseas Medical Demand Offsets Canadian Revenue Drop

Cannabis operators with European medical exposure are seeing growth while domestic reimbursement changes weigh on Canadian sales.

Updated on Nov. 7, 2026 in Economic Indicators

Wide view of a long glass-roofed greenhouse with rows of green plants under soft overcast daylight, with stacked plain crates at the far edge.
Aurora Cannabis reported fiscal second-quarter net revenue of C$86 million, with international medical sales rising 44% to C$61.4 million as Canadian medical revenue fell 24%. AI Illustration. Upload story photo >

Aurora Cannabis reported fiscal second-quarter net revenue of C$86 million for the quarter ended Sept. 30, up from C$78.8 million a year earlier, while adjusted net income fell to C$3.1 million from C$12 million. Growth came from international medical cannabis sales, which operators in Europe-facing supply chains should watch closely.

Why it matters

International medical cannabis revenue rose 44% to C$61.4 million on higher patient demand in Germany and Poland, while Canadian medical revenue fell 24% after changes to the federal reimbursement program. The shift shows how reimbursement rules and cross-border demand are reshaping where revenue comes from in the sector.

Net revenue rose 9% to C$86 million for the quarter ended Sept. 30, compared with C$78.8 million a year earlier. International medical cannabis revenue grew 44% to C$61.4 million, while consumer cannabis revenue fell to C$1.6 million from C$6.9 million.

The players

Aurora Cannabis

A Canadian licensed cannabis producer with medical and consumer cannabis operations across Canada and international markets, including Germany and Poland.

The details

Adjusted net income fell by C$8.9 million, driven mainly by a C$2.5 million increase in adjusted selling, general and administrative expenses, partly offset by a C$1.1 million gain in adjusted gross profit before fair value adjustments. Unfavorable foreign exchange movements of C$4.7 million and a C$0.8 million drop in interest and other income also weighed on the result. The net loss from continuing operations narrowed to C$21.1 million from C$27.2 million over the same period.

Timeline

  1. Quarter ended Sept. 30, 2026: fiscal second-quarter reporting period covered by the results.

Market Landscape

Aurora's revenue mix is shifting away from Canada toward European medical markets, a pattern shaped by domestic reimbursement changes. Its quarter illustrates how producers with international medical exposure are relying on overseas demand as the home market tightens.

Operators in cannabis-adjacent supply chains should weigh the margin pressure from rising selling and administrative costs against the growth in international medical demand. Businesses tied to Canadian medical reimbursement should model revenue scenarios that assume further program changes.

The takeaway

The main operating insight is that overseas medical demand is offsetting domestic reimbursement pressure, but higher costs are eroding profit even as revenue grows. Operators should track the next quarter's selling and administrative expense trend and any further Canadian reimbursement changes before assuming the growth will hold.

Further reading

For broader context on the figures behind companies like this, see Economic Indicators.

Source note: This article includes information reported by TokenPost.